Neurology Conference Market Analysis and Reports | Germany Conference Series

Market Analysis - Neurology Conference 2018

Introduction to Global report of Neurology and Neurological disorders

Neurological disorders are the complications in medical field that affects neural system that includes brain, spinal cord and other nerves. The symptoms for the neurological disorders are possibly mild such as muscle weakness and poor coordination. It is observed in some cases that the symptoms are more noticeable like seizures, pain and intellectual disability. According to WHO report by the year 2020 about 14.1% of the world population will suffer from some form of neurological disorders. The neurological disorders represents more than 100 diseases and disorders that cause hardship in the life of billions families worldwide and many billions dollars in medical expenses.

The most prevalence neurological disorders are:

·         Headaches

·         Migraine

·         Alzheimer's disease and other dementias

·         Medication overuse headaches

12 out of every 100 persons die as a result of neurological disorders. Hence it represents a high societal burden.

In fig 1: The rates of increment in some cases per one lakh are:

·         Alzheimer's (2.4 percent)

·         Motor neuron disease (3.1 percent)

·         Parkinson's (15.7 percent)

·         Brain and nervous system cancers (8.9 percent)

As indicated by WHO report, the number of disability-adjusted life years (DALYs) lost because of neurological illnesses is expected to grow from 95 million worldwide in 2015 to 103 million in 2030. North America has the largest share in neurotherapeutic drugs markets due to rising prevalence of neurological diseases and regular technological advancements. Europe region have second largest neurotherapeutic drugs treatment market trailed by Asia-Pacific and Rest of the World. As per the reports during 2017-2025, Asia Pacific region observed as the fastest growing region due to increasing prevalence of neurological disorders, developing healthcare infrastructure, rising awareness associated with neurological diseases which is the driving rate of diagnosis and mounting an accessibility of modern day treatments in developing countries like India, China, Indonesia.

According to Credence Research report, Neurological Diseases Treatment market was valued at USD 75.3 Bn in 2016, and is expected to reach USD 130.8 Bn by 2025, expanding at a CAGR of 6.2% from 2017 to 2025. Drugs for multiple sclerosis, Alzheimer's disease, and Parkinson's disease control approximately 99% of the total market share.

The key players in the market for Neurological Diseases are:

·         Bayer AG

·         GlaxoSmithKline plc

·         Teva Pharmaceutical Industries Ltd.

·         Merck & Co.

·         Boehringer Ingelheim GmbH

·         Astra Zeneca

·         F-Hoffmann-La Roche Ltd. And others.


According to a report, the worldwide neurology was valued US$5.0B in 2012 and is expected to grow up to US$13.6B in 2019, at a CAGR of 15.4%. Neurological issue such Alzheimer's ailment, ischemic stroke, numerous sclerosis, brain cancer, and other such injuries to the cerebrum are the growth factors of the global neurology device market. Furthermore, as a geriatric population is growing, the worldwide neurology gadgets witnessing is likewise seeing an immense encouragement.

Drugs approved by FDA for Neurology in the year 2017:

·         Austedo (deutetrabenazine)-Teva Pharmaceuticals

·         Brineura (cerliponase alfa)-BioMarin

·         Gocovri (amantadine)-Adamas Pharmaceuticals

·         Ingrezza (valbenazine)-Neurocrine Biosciences

·         Radicava (edaravone)-Mitsubishi Tanabe Pharma

·         Xadago (safinamide)-Newron Pharmaceuticals


The Europe neurological disorder sedate market obliges an extensive variety of diseases. Nonetheless, analyst anticipates that the cerebrovascular diseases segment is expected to grow at a CAGR of 6.9% in the forecast period. Out of all nations like Germany, France, Italy, Spain, UK, Russia, Switzerland, Netherlands, Poland, and Rest of Europe. Of these, Germany is subjected to outperform all others as the country's neurological disorders drugs and is expected to grow at a CAGR of 6.8% in the between of 2016 and 2024.

Some of the major Neurological diseases in Europe are:

·         Epilepsy

·         Alzheimer’s disease

·         Parkinson’s disease

·         Multiple Sclerosis

·         Cerebrovascular disease

·         Others


Some of the major pharmaceutical contributors for Neurological disorders are:

·         AstraZeneca

·         GlaxoSmithKline

·         Merck

·         Sanofi

·         Pfizer

·         Roche

·         Novartis              

·         Johnson & Johnson


Fast Facts about Neurological Diseases are:

Neuromuscular Diseases

Myasthenia Gravis is an autoimmune disease that affects the neuromuscular junction. With a prevalence of 150-250 cases per 1 million, MG and its subgroups are the major disorders that affect neuromuscular junction.
Multiple Sclerosis is an inherited disorder.  According to the estimation of Multiple Sclerosis Foundation, about 2.5 MN people around the world have MS. The ration of men with MS to women with the disease is 1 to 2. Amyotrophic lateral sclerosis is a progressive neurological disorder that affects the function of nerves and muscles. According to an estimation ALS is the cause of five in every 100, 000 deaths in people ages 20 or older
Spinal Muscular Atrophy is a fatal autosomal recessive disorder which affects 1 in 40 people that carries SMA gene. It causes progressive muscle wasting and paralysis.

Peripheral nerves

Peripheral Neuropathy is the common condition that affects 2.4% of the total population. Hence its prevalence increases to 8% with growing age.
Diabetic Sensorimotor Polyneuropathy, a polyneuropathy disease which may be present 66% of type 1 diabetic patients as compared to 59% in type 2 diabetic patients.

Child Neurology

According to Global Business Intelligence Research report, the epilepsy therapeutic market value in major countries (US, France, Canada, Germany, Italy, Japan, and Spain) will increase at modest CAGR of 3.9%.
The epilepsy therapeutic market in 2012 is $3.4 billion which extended up to $4.5 billion by 2019.
In case of Epilepsy diseases, North America market is the most mature market, which is expected to reach with an estimated value of over USD 2,500 million by 2024.
Some of the key players in Epilepsy drug market are Sanofi S.A, Abbott Laboratories, Inc., Sunovion Pharmaceuticals, Inc., UCB Pharma Ltd., Johnson & Johnson, Novartis AG etc.


Neuromodulation is one of the best methods which have the ability to treat pain without relying on medications.
Around 60% patients show improvement in their lifestyle with chronic pain following implantation of peripheral nerve stimulators.
In clinical trials, after getting a treatment with Spinal Cord Stimulation (SCS), approximately 59% patients suffered from chronic pain reported excellent pain relief.
Deep Brain Stimulation (DBS) provides long term improvement in the quality of life to the patients suffering from Parkinson’s disease, essential tremor and dystonia.

Movement Disorders

According to Epidemiology studies, The Ataxia prevalence is of around 10 per 100,000 populations and idiopathic ataxia likely outnumbers genetic cases.
Dystonia is a disorder of muscles that causes slow abnormal postures of the musculature that are uncontrolled by the patient. According to a report Global cervical dystonia market is expected to grow at a CAGR of 5% during the forecast period of 2017-2023.
Parkinson’s disease is common age related neurodegenerative disorder. An estimated 10 million people suffer from Parkinson's disease and expected to increase every year. A patient suffered from this disease spends around $2500 per year on the medications to aid in ease of life.


Global Neurosurgical Devices Market is expected to grow at a CAGR around 9% during the forecast period.
Nearly 13.46% of the global population suffering from neurological disorders. Some of the most prevalent diseases are Epilepsy, Parkinson’s Diseases, Alzheimer diseases and Neuro-infections. Neurological disorders are the cause behind the 10% of death all over the world.
According to a report Global Neurosurgical Devices Market is expected to grow at a CAGR of 10.5% between the forecast periods of 2017-2023.


Neurological diseases give their impact to estimated 100 million Americans every year. The cost of Stroke and Dementia alone expected to figure more than $600 billion by 2030.
According to a report, estimated 5.5 million Americans are living with Alzheimer’s disease in 2017. Two-thirds of Americans with Alzheimer’s are women.
The Alzheimer's disease Therapeutics and Diagnostics Market reached at $6.71bn in the year 2016. The Alzheimer's disease Therapeutics and diagnostics Market is expected to grow at a CAGR of 15.3% in the 2nd half of the forecasted period.


The global epilepsy drug market is expected to grow at CAGR of 5% in the second half of the forecast period. In 2016, the global Epilepsy drug market is $4.3bn and is expected to grow at $6.9bn in 2027.
Epilepsy is one of the most common neurological disorders globally that affect approximately 50 million peoples worldwide.
On estimation 2.4 million peoples are diagnosed with epilepsy each year. Almost 80% peoples suffer from epilepsy lived in low and middle income countries.
The most common type of epilepsy is Idiopathic epilepsy which has no identifiable cause which affects 6 out of 10 people.

Neurodevelopment disorders

According to the reports of Persistence Market research ADHD therapeutics market is expected to expand at a CAGR of 6.2% during forecast period 2015 – 2024. The market segmentation based on the drug type, age group, distribution channel and region.
The Lisdexamfetamine Dimesylate drug type sub-segment is expected to grow at highest CAGR of 15.6% in value terms during the forecast period. 
In USA, 11% of children between the age of 4 and 17 and of total 4.4% of adults suffered from the ADHD Diseases.

Neurodegenerative disorders

The global Central Nervous System (CNS) therapeutic market size was worth USD 77.2 billion in 2016 and is anticipated to grow at a CAGR of 5.9% during the forecast period.
Global multiple sclerosis market is rapidly growing and it is expected to cross US$ 20 Billion by 2022.


According to technavio report, the global acute ischemic stroke (AIS) therapeutics markets to grow at a CAGR of more than 2% of during the forecast period.
Global myasthenia gravis drugs market to grow at a CAGR of 13.16% during the forecast period 2017-2021.

Neuro Endocrinology

The global Huntington’s disease therapeutics market to grow at a CAGR of 14.75% during the period 2017-2021

Central Nervous System

According to a report Central Nervous System (CNS) Disorders Therapeutics Market to grow at 5.59% CAGR during the period 2016-2020. And, is expected to reach $128.9 Billion.
Global mental health therapeutics revenue accounted for 48% share in 2016 and is expected to grow at a significant rate from 2016 to 2025.

Brain Disorders

The global brain monitoring devices market is expected to grow at a CAGR of 6.5% and 7.0% during the forecasting period 2017-2023 and is expected to touch the figure of $10,011.5 million by 2023.

Spinal Cord Injury

Spinal cord injuries affect over 40K people in the UK and around 270,000 in the US.
There are 12K new cases of spinal cord injury in the US each year.
According to a report, Global Slip Disc markets grow at the CAGR of ~5.4% during the forecast period and are expected to reach USD 11,011.3 million by 2023.


According to Research and Markets report, the global dementia and movement disorder treatment market to grow at a CAGR of 4.48% during the period 2017-2021.
On estimation, 850, 000 people are living with dementia in the UK.
Globally, the people suffer from Dementia will increase from 46.8m in 2015 to 131.5m in 2050, a 281% increase

Neuro Oncology

According to the reports, the radiation Oncology market size is expected to reach USD 10.1 billion by 2025.

Parkinson’s Diseases

According to the WHO, the number of people with disability-adjusted life year due to Parkinson’s disease was 1.7 million globally in 2015.
According to European Parkinson’s Disease Association, the cost of treatment for this disease in Europe was estimated at US$ 12.6 Million in 2005 and is expected to double by 2030.
As per the European Brain Council around 6.3 million people suffer from Parkinson’s disease.
Parkinson incident rates increase with aging and the percentage of the world’s population above the age of 65 years will increase from 7% to 16% from 2000-2050 will serve this market as a driver.


Some major Neurology Centres in Europe:

·         Grupo Hospitalario Quirón, Spain

·         Clinic Hirslanden & Clinic Im Park, Switzerland

·         British Hospital Lisbon XXI, Portugal

·         Anadolu Medical Center, Turkey

·         Centro Médico Teknon, Spain

·         Hospital Ruber Internacional, Spain

·         HM Hospitales, Spain

·         Sant Joan de Déu-Barcelona Children's Hospital, Spain

·         Vithas Xanit International Hospital, Spain

·         Hygeia Hospital, Greece


List of Medical Universities in Germany

·         Heidelberg University

·         RWTH Aachen University

·         Lubeck University

·         Witten/Herdecke University

·         Magdeburg University

·         Munster University

·         Wurzburg University

·         Tubingen University

·         Freiburg University

·         Leipzig University